Listed

Kazia Therapeutics Ltd: Form 20-F for the period ended Jun 30, 2021

Filed with the SEC on Oct 7, 2021 and accepted by EDGAR at Oct 7, 2021, 07:12 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2020-07-01 to 2021-06-30AUD 15.2mifrs-full:RevenueFromContractsWithCustomers
Income tax12 months2020-07-01 to 2021-06-30−AUD 484.0kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2020-07-01 to 2021-06-30−AUD 8.4mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2020-07-01 to 2021-06-30−AUD 7.16ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2020-07-01 to 2021-06-30−AUD 7.16ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2020-07-01 to 2021-06-30−AUD 9.1mifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2021-06-30AUD 27.6mifrs-full:CashAndCashEquivalents
Current assetsAt period end2021-06-30AUD 29.4mifrs-full:CurrentAssets
Total assetsAt period end2021-06-30AUD 58.1mifrs-full:Assets
Current liabilitiesAt period end2021-06-30AUD 8.3mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2021-06-30AUD 20.2mifrs-full:Liabilities
Shareholders' equityAt period end2021-06-30AUD 37.9mifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2021-06-30132,012,209 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001193125-21-293688. Last ingested by Listed: Nov 2, 2026, 16:21 ET. Listed shows no prices and gives no investment advice.